Dual inhibition of NOX2 and receptor tyrosine kinase by BJ-1301 enhances anticancer therapy efficacy via suppression of autocrine-stimulatory factors in lung cancer

Molecular Cancer Therapeutics

Volumn 16, Issue 10, 2017, Pages 2144-2156

  Gautam, Jaya ^a   Ku, Jin Mo ^b   Regmi, Sushil Chandra ^a   Jeong, Hyunyoung ^c   Wang, Ying ^a   Banskota, Suhrid ^a   Park, Myo Hyeon ^a   Nam, Tae gyu ^d   Jeong, Byeong Seon ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

^b Gyeonggi Institute of Science and Technology Promotion   (South Korea)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BJ 1301; CISPLATIN; PROTEIN TYROSINE KINASE; PYRIDINOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUNITINIB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER; LUNG CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHICKEN; DRUG EFFECT; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); OXIDATION REDUCTION REACTION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; HUMANS; LUNG NEOPLASMS; MICE; NADPH OXIDASE 2; NEOVASCULARIZATION, PATHOLOGIC; OXIDATION-REDUCTION; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85030632173     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0915     Document Type: Article

References (59)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
2. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29:2121–7.
3. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706–13.
4. Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol 2014;4:204.
5. Suleiman AA, Nogova L, Fuhr U. Modeling NSCLC progression: recent advances and opportunities available. AAPS J 2013;15:542–50.
6. Babior BM. NADPH oxidase. Curr Opin Immunol 2004;16:42–7.
7. Krause KH. Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 2004;57:S28–9.
8. Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ. NADPH oxidases in vascular pathology. Antioxid Redox Signal 2014;20:2794–814.
9. Takac I, Schrodër K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep 2012;14:70–8.
10. Roy K, Wu Y, Meitzler JL, Juhasz A, Liu H, Jiang G, et al. NADPH oxidases and cancer. Clin Sci 2015;128:863–75.
11. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276–85.
12. Liu L, Rezvani HR, Back JH, Hosseini M, Tang X, Zhu Y, et al. Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generation. PLoS One 2014;9:e97245.
13. Banskota S, Regmi SC, Kim JA. NOX1 to NOX2 switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7. Mol Cancer 2015;14:1.
14. Okamura N, Sakai T, Nishimura Y, Sakai M, Araki S, Yamaguchi M, et al. Decavanadate inhibits the cell-free activation of neutrophil NADPH oxidase without affecting tyrosine phosphorylation. Biol Pharm Bull 1999; 22:799–804.
15. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 2002;277:3101–8.
16. Paletta-Silva R, Rocco-Machado N, Meyer-Fernandes JR. NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity. Int J Mol Sci 2013;14:3683–704.
17. Anrather J, Racchumi G, Iadecola C. NF-kB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006; 281:5657–67.
18. Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res 2008;68:1037–45.
19. Han M, Zhang T, Yang L, Wang Z, Ruan J, Chang X. Association between NADPH oxidase (NOX) and lung cancer: a systematic review and meta-analysis. J Thorac Dis 2016;8:1704.
20. Block K, Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer 2012;12:627–37.
21. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–8.
22. Monte M, Davel L, de Lustig ES. Hydrogen peroxide is involved in lymphocyte activation mechanisms to induce angiogenesis. Eur J Cancer 1997;33:676–82.
23. Wells SR, Jennings MH, Rome C, Hadjivassiliou V, Papas KA, Alexander JS. Alpha-, gamma- and delta-tocopherols reduce inflammatory angiogenesis in human microvascular endothelial cells. J Nutr Biochem 2010;21: 589–97.
24. Monte M, Davel LE, De Lustig ES. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic Biol Med 1994;17: 259–66.
25. Abid M, Kachra Z, Spokes KC, Aird WC. NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett 2000;486: 252–6.
26. Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intra-membrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med 1991;10:263–75.
27. Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, et al. Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency. Biochemistry 1993;32:10692–9.
28. McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 2000;224:292–301.
29. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008;123:739–52.
30. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37–46.
31. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Libr 2012.
32. Nam T-G, Ku J-M, Park H-G, Porter NA, Jeong BS. New synthetic route to N-tocopherol derivatives: synthesis of pyrrolopyridinol analogue of a-tocopherol from pyridoxine. Org Biomol Chem 2011;9:1749–55.
33. Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, et al. The antiangiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol 2009;50:123–31.
34. Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, etal. Tryptophan hydroxylase 1 and 5-HT 7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer 2016;15:75.
35. Kim JA, Cho KB, Kim MR, Park BC, Kim SK, Lee MY, et al. Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells. Cancer Lett 2008;268:225–32.
36. Regmi SC, Park SY, Ku SK, Kim JA. Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species. Free Radic Biol Med 2014;69:377–89.
37. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling? In control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–71.
38. Kumar R, Crouthamel M, Rominger D, Gontarek R, Tummino P, Levin R, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717–23.
39. Heppner DE, Hristova M, Dustin CM, Danyal K, Habibovic A, van der Vliet A. The NADPH oxidases DUOX1 and NOX2 play distinct roles in redox regulation of epidermal growth factor receptor signaling. J Biol Chem 2016;291:23282–93.
40. Kim DG, Kang Y, Lee H, Lee EK, Nam T-G, Kim JA, et al. 6-Amino-2, 4, 5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity. Eur J Med Chem 2014;78:126–39.
41. Marin M, Giner RM, Rios JL, del Carmen Recio M. Protective effect of apocynin in a mouse model of chemically-induced colitis. Planta Med 2013;79:1392–400.
42. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006; 344:200–5.
43. Park SY, Lee JS, Ko YJ, Kim AR, Choi MK, Kwak MK, et al. Inhibitory effect of simvastatin on the TNF-a-and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Arch Pharm Res 2008; 31:195–204.
44. Banskota S, Gautam J, Regmi SC, Gurung P, Park MH, Kim SJ, et al. BJ-1108, a 6-amino-2, 4, 5-trimethylpyridin-3-ol analog, Iihibits serotonin-induced angiogenesis and tumor growth through PI3K/NOX pathway. PLoS One 2016;11:e0148133.
45. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glyco-protein-mediated multidrug resistance. Eur J Pharm Sci 2001;14:29–36.
46. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681–6.
47. Reiners JJ, Lee JY, Clift RE, Dudley DT, Myrand SP. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol 1998;53:438–45.
48. Choi M, Hwang YS, Kumar AS, Jo H, Jeong Y, Oh Y, et al. Design and synthesis of 3, 4-dihydro-2H-benzo [h] chromene derivatives as potential NF-kB inhibitors. Bioorg Med Chem Lett 2014;24:2404–7.
49. Watamoto T, Egusa H, Sawase T, Yatani H. Screening of pharmacologically active small molecule compounds identifies antifungal agents against Candida Biofilms. Front Microbiol 2014;6:1453.
50. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A 1997;94:5826–30.
51. Lodewijk V, Leitges M, Altschuler G, Mistry N, Mcdermott A, Jurgen R, et al. Protein kinase C-b contributes to NADPH oxidase activation in neutro-phils. Biochem J 2000;347:285–9.
52. Kinsella BT, Erdman R, Maltese W. Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J Biol Chem 1991;266:9786–94.
53. Venugopal SK, Devaraj S, Yang T, Jialal I. Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes 2002;51: 3049–54.
54. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation 2006;3:30.
55. Egger T, Hammer A, Wintersperger A, Goti D, Malle E, Sattler W. Modulation of microglial superoxide production by a–tocopherol in vitro: attenuation of p67phox translocation by a protein phosphatasedependent pathway. J Neurochem 2001;79:1169–82.
56. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006;6:65–75.
57. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J, et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1996;4:176–82.
58. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor–c-kit autocrine signaling loop. Cancer Res 2010;70:338–46.
59. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1.